KPRX

NASDAQ

Kiora Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

$2.45-0.04 (-1.61%)

News25/Ratings1

Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is based in Salt Lake City, Utah.

Price$2.45-0.01 (-0.41%)

05:45 PM07:45 PM

News · 26 weeks18-25%

2025-10-262026-04-19

Mix1590d

Insider8(53%)
SEC Filings6(40%)
Other1(7%)

Latest news

25 items

2dSEC
SEC Form D filed by Kiora Pharmaceuticals Inc.
D - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
16dSEC
Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
21dINSIDER
SEC Form 4 filed by Tosca Melissa
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
21dINSIDER
SEC Form 4 filed by Daniels Eric Joseph
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
21dINSIDER
SEC Form 4 filed by Strem Brian M.
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
21dSEC
Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
29dSEC
SEC Form S-8 filed by Kiora Pharmaceuticals Inc.
S-8 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
29dSEC
Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
29dSEC
SEC Form 10-K filed by Kiora Pharmaceuticals Inc.
10-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
44dINSIDER
SEC Form 4 filed by Kiora Pharmaceuticals Inc.
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
44dINSIDER
SEC Form 4 filed by Kiora Pharmaceuticals Inc.
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
44dINSIDER
President and CEO Strem Brian M. was granted 16,733 shares, increasing direct ownership by 36% to 62,598 units (SEC Form 4)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
48dINSIDER
Chief Development Officer Daniels Eric Joseph covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.90% to 26,137 units (SEC Form 4)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
48dINSIDER
President and CEO Strem Brian M. covered exercise/tax liability with 238 shares, decreasing direct ownership by 0.52% to 45,865 units (SEC Form 4)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
84dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Kiora Pharmaceuticals Inc.
SCHEDULE 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)
167dSEC
Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
167dSEC
SEC Form 10-Q filed by Kiora Pharmaceuticals Inc.
10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
175dPR
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
ENCINITAS, Calif. and WASHINGTON D.C., Oct. 30, 2025 /PRNewswire/ -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate collaboration among advocacy, research, and industry stakeholders to advance research leading to vision-improving therapies. The Vision Consortium aims to transform the lives of people affected by rare ocular disorders by identifying clinical trial ready populations, ensuring meaningful outcome measures, and accelerating the development of clinical trial programs required to bring new treatments to patients.
214dSEC
SEC Form EFFECT filed by Kiora Pharmaceuticals Inc.
EFFECT - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
220dSEC
SEC Form S-3 filed by Kiora Pharmaceuticals Inc.
S-3 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
258dSEC
Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
258dSEC
SEC Form 10-Q filed by Kiora Pharmaceuticals Inc.
10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
266dPR
Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer
Adam Sachs, Co-Founder, to Remain on as President Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Stephen From as Chief Executive Officer and a member of the Company's Board of Directors (the "Board"), effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company's leadership team. Mr. From brings over 20 years of leadership in the healthcare and financial
323dSEC
Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
324dSEC
Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)